A US Senate sponsor of an OTC drug monograph reform bill expects the legislation to pass this year but also sees a chance that the corresponding user fee program wouldn't be part of the Food and Drug Administration's next appropriation.
"We believe that we're going to get this done and get this passed. It will be up to the FDA to swiftly implement the legislation," said Sen. Bob Casey on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?